GSK statement on UK Government-initiated review of antibiotic resistance

“We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance. This is a positive step towards addressing this global public health threat.

GSK has a 40 year heritage in this field and is one of only a handful of companies still conducting R&D into antibiotics.  

This is a very complex area and new approaches are needed if more companies are to be encouraged to invest in this area.  This needs to include new economic models and more open-minded approaches to sharing information and working with partners across the public and private sectors.”